SELLAS Life Sciences Group, Inc. SLS Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Syndax PharmaceuticalsSNDX

——

CRISPR TherapeuticsCRSP

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue-—

Gross profit-—

Operating income-$9.3M-52.6%

Net income-$8.4M-44.6%

EPS (diluted)-$0.05+28.6%

Balance sheet

See full

Cash & equivalents$107.1M+277%

Total debt$871.0K+0.1%

Total equity$107.4M+287%

Total assets$114.2M+227%

Cash flow

See full

Operating cash flow-$8.8M+2.5%

Valuation

See full

Market cap$1.8B+674%

Enterprise value$1.7B+826%

Profitability

See full

Gross margin90%-7.4pp

Operating margin-4,195%-4,591pp

Net margin-4,130.1%-4,444pp

FCF margin-300.5%—

Returns & leverage

See full

Return on equity-43.6%-17.9pp

Debt / equity0×0.0×

Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s increase (decrease) in prepaid expense and other assets?: SELLAS Life Sciences Group, Inc. (SLS) reported increase (decrease) in prepaid expense and other assets of $652K in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s increase (decrease) in prepaid expense and other assets changed year-over-year?: SELLAS Life Sciences Group, Inc.'s increase (decrease) in prepaid expense and other assets decreased by 42.4% year-over-year, from $1.13M to $652K.